44.23
Ptc Therapeutics Inc stock is traded at $44.23, with a volume of 1.54M.
It is up +4.05% in the last 24 hours and up +3.46% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$42.51
Open:
$44.29
24h Volume:
1.54M
Relative Volume:
1.46
Market Cap:
$3.96B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-7.4461
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
-11.45%
1M Performance:
+3.46%
6M Performance:
-0.11%
1Y Performance:
+42.45%
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
PTCT
Ptc Therapeutics Inc
|
44.23 | 3.96B | 900.66M | -453.20M | -274.19M | -5.94 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
May-07-25 | Upgrade | Citigroup | Sell → Neutral |
Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
Mar-07-25 | Initiated | Scotiabank | Sector Perform |
Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Sep-04-24 | Initiated | Robert W. Baird | Outperform |
Aug-26-24 | Resumed | UBS | Buy |
May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Dec-08-23 | Initiated | Wells Fargo | Overweight |
Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
Oct-06-23 | Downgrade | Truist | Buy → Hold |
Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
Mar-17-23 | Initiated | SVB Securities | Market Perform |
Dec-14-22 | Initiated | Goldman | Sell |
Sep-12-22 | Initiated | Jefferies | Buy |
Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
Sep-01-22 | Initiated | Citigroup | Buy |
Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
Apr-26-21 | Resumed | Credit Suisse | Neutral |
Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
Oct-28-20 | Initiated | UBS | Neutral |
Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
Aug-25-20 | Initiated | Raymond James | Outperform |
Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-12-19 | Initiated | SunTrust | Buy |
May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Apr-11-19 | Initiated | Bernstein | Outperform |
Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
Jul-19-18 | Initiated | Credit Suisse | Outperform |
Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Driehaus Capital Management LLC Makes New $46.99 Million Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
AQR Capital Management LLC Sells 32,230 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
William Blair Boosts Earnings Estimates for PTC Therapeutics - Defense World
JPMorgan Chase & Co. Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $67.00 - Defense World
PTC Therapeutics (NASDAQ:PTCT) Upgraded at Citigroup - Defense World
Tudor Investment Corp ET AL Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lost Money on PTC Therapeutics, Inc. (PTCT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Shareholders Who Lost Money on PTC Therapeutics, Inc. (PTCT) Should Contact Levi & Korsinsky About Securities Fraud InvestigationPTCT - ACCESS Newswire
B of A Securities Upgrades PTC Therapeutics (PTCT) - Nasdaq
PTC Therapeutics (NASDAQ:PTCT) Shares Gap Up Following Strong Earnings - MarketBeat
Cantor Fitzgerald Cuts PTC Therapeutics (NASDAQ:PTCT) Price Target to $112.00 - MarketBeat
BofA Upgrades PTC Therapeutics to Buy From Neutral, Adjusts Price Target to $68 From $55 - marketscreener.com
PTC Therapeutics (NASDAQ:PTCT) Raised to Neutral at Citigroup - MarketBeat
Baker BROS. Advisors LP Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics (PTCT) Receives Upgrade from BofA with New Price Target | PTCT Stock News - GuruFocus
PTCT: Barclays Lowers Price Target for PTC Therapeutics to $42 | PTCT Stock News - GuruFocus
ATTENTION PTCT SHAREHOLDERS: Investors who lost money on PTC Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
PTC Therapeutics, Inc. (PTCT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2025 Earnings Call Transcript - Insider Monkey
PTCT: Barclays Reduces Price Target for PTC Therapeutics | PTCT Stock News - GuruFocus
Blackstone Inc. Cuts Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha
PTC Therapeutics projects $650M to $800M revenue for 2025 amid global SUFIANCE launch preparations - MSN
Schonfeld Strategic Advisors LLC Has $5.52 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Price T Rowe Associates Inc. MD Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTCT: Baird Adjusts Price Target for PTC Therapeutics | PTCT Stock News - GuruFocus
PTCT Analyst Raises Price Target Amid Outperform Rating | PTCT Stock News - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Shares Gap DownHere's What Happened - MarketBeat
Earnings call transcript: PTC Therapeutics beats Q1 2025 revenue forecast By Investing.com - Investing.com UK
PTC Therapeutics (PTCT) Target Price Adjusted by Cantor Fitzgerald | PTCT Stock News - GuruFocus
PTC Therapeutics to Participate at Upcoming Investor Conferences - Seeking Alpha
PTC Therapeutics, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by PTC Therapeutics, Inc. (PTCT) - ACCESS Newswire
PTC Therapeutics (PTCT) Price Target Lowered by JP Morgan | PTCT Stock News - GuruFocus
PTC Therapeutics upgraded by Citigroup with a new price target - Quantisnow
PTCT Stock Target Price Adjusted by Baird Analyst | PTCT Stock News - GuruFocus
Citigroup Upgrades PTC Therapeutics (PTCT) - Nasdaq
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
JPMorgan Adjusts Price Target for PTC Therapeutics (PTCT) | PTCT Stock News - GuruFocus
Citigroup Upgrades PTC Therapeutics to Neutral From Sell, Adjusts Price Target to $40 From $50 - marketscreener.com
48,728 Shares in PTC Therapeutics, Inc. (NASDAQ:PTCT) Bought by Raymond James Financial Inc. - MarketBeat
PTC Therapeutics Swings to Q1 Earnings, Revenue Increases - marketscreener.com
PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
PTC Therapeutics Inc (PTCT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Decoding PTC Therapeutics Inc (PTCT): A Strategic SWOT Insight - GuruFocus
PTC Therapeutics Reports Strong Q1 2025 Results - TipRanks
An Investigation Has Commenced on Behalf of PTC Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your PTCT Losses - ACCESS Newswire
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - Citizen Tribune
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc.PTCT - PR Newswire
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):